0001654954-22-004490.txt : 20220401 0001654954-22-004490.hdr.sgml : 20220401 20220401172829 ACCESSION NUMBER: 0001654954-22-004490 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220401 DATE AS OF CHANGE: 20220401 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mazar Andrew Paul CENTRAL INDEX KEY: 0001727393 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 22799518 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD STREET 2: SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 4 1 section16.xml PRIMARY DOCUMENT X0306 4 2022-03-31 false 0001645469 Monopar Therapeutics MNPR 0001727393 Mazar Andrew Paul 1000 SKOKIE BLVD STE 350 WILLMETTE IL 60091 true true false Chief Scientific Officer Common Stock 2022-03-31 4 M false 1606 A 22595.8 D Common Stock 2022-03-31 4 F false 471 2.55 D 22124.8 D Common Stock 4111272.88 I See Footnote Common Stock 166667 I See Footnote Restricted Stock Units 2022-03-31 4 M false 1606 0 D Common Stock 1606 88792 D Represents shares acquired on vesting and settlement of restricted stock units. This is based upon the 4,111,272.88 shares of Monopar Common Stock that Tactic Pharma LLC indirectly controls through TacticGem LLC. As a manager of Tactic Pharma LLC, Dr. Mazar may be deemed to share voting and dispositive power over these 4,111,272.88 shares. Dr. Mazar disclaims beneficial ownership of the 4,111,272.88 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein. This is based upon the 166,667 shares of Monopar Common Stock that Tactic Pharma LLC directly owns. As a manager of Tactic Pharma LLC, Dr. Mazar may be deemed to share voting and dispositive power over these 166,667 shares. Dr. Mazar disclaims beneficial ownership of the 166,667 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein. On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. /s/ Kim R. Tsuchimoto, Attorney-in-fact 2022-04-01